Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02294227 · ClinicalTrials.gov registry record · Phase 3
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
A Phase 3 study of Arthritis, Psoriatic, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 341
- Enrollment target
- 20
- Study locations
NCT02294227 is a Phase 3 study of Arthritis, Psoriatic that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 341 participants, below the 555-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT02294227, a Phase 3 study of Arthritis, Psoriatic, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 341 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and maintenance dosing using pre-filled syringe (PFS) and to assess efficacy, safety and tolerability up to 2 years in subjects with active PsA despite current or previous NSAID or DMARD therapy
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Secukinumab
Study Locations (20)
Florida
- Novartis Investigative Site - Palm Harbor
- Novartis Investigative Site - Sarasota
South Carolina
- Novartis Investigative Site - Charleston
- Novartis Investigative Site - Greenville
Washington
- Novartis Investigative Site - Seattle
- Novartis Investigative Site - Seattle
Arizona
- Novartis Investigative Site - Mesa
California
- Novartis Investigative Site - Upland
Colorado
- Novartis Investigative Site - Denver
Illinois
- Novartis Investigative Site - Peoria
Louisiana
- Novartis Investigative Site - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2015-05-29 |
| Est. Completion | 2017-12-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02294227
The ClinicalTrials.gov registry entry for NCT02294227 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 555-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (39% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02294227 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Florida, South Carolina, Washington.
Frequently Asked Questions
What is clinical trial NCT02294227 about?
NCT02294227 is a clinical study titled "16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis". The purpose of this study was to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and maintenance dosing using pre-filled syringe (PFS) and to assess efficacy, s...
What is the current status of trial NCT02294227?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 341 participants. The study started on 2015-05-29. Estimated completion is 2017-12-19.
What conditions does trial NCT02294227 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT02294227?
The interventions under investigation include: Placebo (OTHER), Secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02294227?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02294227 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.